Payment overview · 2025
General Payments
$113.76
7 reported records · 5 companies
Healthcare provider profile · identity verified
Stacie Gilmore, MD
Allopathic & Osteopathic Physicians|Family Medicine · MURPHY, NC · NPI 1154857985
Verified facts
What the public records show
CMS Open Payments records show Stacie Gilmore, MD received $113.76 in general payments during 2025 across 7 reported records.
Novo Nordisk Inc accounted for 32.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Vraylar by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 192 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $36.57 | 32.1% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $29.10 | 25.6% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $17.30 | 15.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.42 | 14.4% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.37 | 12.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $113.76 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $29.10 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $20.19 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $20.19 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $17.30 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $17.30 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $16.42 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.38 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.37 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 192 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 89 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
85 | 23 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
89 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
192 | 38 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 693 | 150 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 646 | 162 |
| Atorvastatin Calcium | Atorvastatin Calcium | 636 | 164 |
| Lisinopril | Lisinopril | 608 | 138 |
| Omeprazole | Omeprazole | 574 | 145 |
| Amlodipine Besylate | Amlodipine Besylate | 494 | 125 |
| Losartan Potassium | Losartan Potassium | 385 | 106 |
| Alprazolam | Alprazolam | 330 | 56 |
| Trazodone Hcl | Trazodone Hcl | 310 | 75 |
| Montelukast Sodium | Montelukast Sodium | 302 | 74 |
| Hydrochlorothiazide | Hydrochlorothiazide | 300 | 81 |
| Gabapentin | Gabapentin | 282 | 84 |
| Fluticasone Propionate | Fluticasone Propionate | 262 | 80 |
| Famotidine | Famotidine | 240 | 64 |
| Potassium Chloride | Potassium Chloride | 225 | 58 |
| Pantoprazole Sodium | Pantoprazole Sodium | 223 | 52 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 218 | 50 |
| Metoprolol Tartrate | Metoprolol Tartrate | 207 | 49 |
| Furosemide | Furosemide | 197 | 57 |
| Tamsulosin Hcl | Tamsulosin Hcl | 196 | 57 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 192 | 58 |
| Ozempic | Semaglutide | 192 | 38 |
| Metformin Hcl | Metformin Hcl | 190 | 47 |
| Metoprolol Succinate | Metoprolol Succinate | 187 | 54 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 177 | 63 |
| Duloxetine Hcl | Duloxetine Hcl | 168 | 43 |
| Tramadol Hcl | Tramadol Hcl | 166 | 53 |
| Meloxicam | Meloxicam | 165 | 48 |
| Zolpidem Tartrate | Zolpidem Tartrate | 163 | 38 |
| Clonazepam | Clonazepam | 154 | 27 |
| Citalopram Hbr | Citalopram Hydrobromide | 152 | 38 |
| Fluoxetine Hcl | Fluoxetine Hcl | 142 | 38 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 139 | 31 |
| Mounjaro | Tirzepatide | 136 | 29 |
| Oxycodone Hcl | Oxycodone Hcl | 135 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 134 | 33 |
| Lorazepam | Lorazepam | 127 | 25 |
| Simvastatin | Simvastatin | 126 | 27 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 123 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 122 | 31 |
| Alendronate Sodium | Alendronate Sodium | 120 | 28 |
| Pregabalin | Pregabalin | 118 | 28 |
| Celecoxib | Celecoxib | 111 | 31 |
| Prednisone | Prednisone | 109 | 66 |
| Carvedilol | Carvedilol | 106 | 26 |
| Ibuprofen | Ibuprofen | 101 | 25 |
| Glipizide | Glipizide | 95 | 25 |
| Sertraline Hcl | Sertraline Hcl | 94 | 27 |
| Buspirone Hcl | Buspirone Hcl | 93 | 29 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 93 | 22 |
| Atenolol | Atenolol | 90 | 21 |
| Metformin Hcl Er | Metformin Hcl | 90 | 25 |
| Tizanidine Hcl | Tizanidine Hcl | 90 | 34 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 89 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 86 | 23 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 86 | 33 |
| Methocarbamol | Methocarbamol | 85 | 21 |
| Synthroid | Levothyroxine Sodium | 85 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 84 | 23 |
| Ezetimibe | Ezetimibe | 81 | 24 |
| Doxycycline Hyclate | Doxycycline Hyclate | 78 | 54 |
| Spironolactone | Spironolactone | 78 | 22 |
| Bupropion Xl | Bupropion Hcl | 77 | 22 |
| Paroxetine Hcl | Paroxetine Hcl | 77 | 16 |
| Allopurinol | Allopurinol | 74 | 23 |
| Ropinirole Hcl | Ropinirole Hcl | 73 | 22 |
| Diazepam | Diazepam | 72 | 18 |
| Jardiance | Empagliflozin | 72 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 71 | 29 |
| Amitriptyline Hcl | Amitriptyline Hcl | 70 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 70 | 62 |
| Glipizide Er | Glipizide | 70 | 20 |
| Ibandronate Sodium | Ibandronate Sodium | 69 | 16 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 62 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 62 | 18 |
| Xarelto | Rivaroxaban | 61 | 17 |
| Liothyronine Sodium | Liothyronine Sodium | 60 | 15 |
| Meclizine Hcl | Meclizine Hcl | 58 | 24 |
| Propranolol Hcl | Propranolol Hcl | 58 | 11 |
| Donepezil Hcl | Donepezil Hcl | 57 | 18 |
| Fluconazole | Fluconazole | 56 | 35 |
| Baclofen | Baclofen | 55 | 16 |
| Ventolin Hfa | Albuterol Sulfate | 55 | 16 |
| Fenofibrate | Fenofibrate | 54 | 11 |
| Finasteride | Finasteride | 54 | 14 |
| Eliquis | Apixaban | 53 | 14 |
| Clonidine Hcl | Clonidine Hcl | 52 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 51 | 11 |
| Estradiol | Estradiol | 50 | 16 |
| Glimepiride | Glimepiride | 45 | 11 |
| Valacyclovir | Valacyclovir Hcl | 45 | 23 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 44 | 35 |
| Lamotrigine | Lamotrigine | 44 | suppressed |
| Levofloxacin | Levofloxacin | 44 | 35 |
| Nifedipine Er | Nifedipine | 44 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 43 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 42 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 42 | 32 |
| Testosterone Cypionate | Testosterone Cypionate | 42 | 11 |
| Mirtazapine | Mirtazapine | 41 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 40 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 40 | 15 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 39 | 22 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 39 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 39 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 38 | 14 |
| Methylprednisolone | Methylprednisolone | 38 | 34 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 37 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 37 | 12 |
| Aripiprazole | Aripiprazole | 36 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 36 | 13 |
| Warfarin Sodium | Warfarin Sodium | 36 | suppressed |
| Cephalexin | Cephalexin | 35 | 28 |
| Divalproex Sodium | Divalproex Sodium | 35 | suppressed |
| Lovastatin | Lovastatin | 35 | 11 |
| Naproxen | Naproxen | 35 | 13 |
| Solifenacin Succinate | Solifenacin Succinate | 35 | suppressed |
| Ketoconazole | Ketoconazole | 33 | 16 |
| Temazepam | Temazepam | 33 | suppressed |
| Torsemide | Torsemide | 33 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 32 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 31 | 13 |
| Nystatin | Nystatin | 31 | 18 |
| Venlafaxine Hcl | Venlafaxine Hcl | 31 | suppressed |
| Acyclovir | Acyclovir | 30 | 11 |
| Azithromycin | Azithromycin | 30 | 27 |
| Sucralfate | Sucralfate | 30 | 13 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 29 | suppressed |
| Colchicine | Colchicine | 28 | 12 |
| Minoxidil | Minoxidil | 28 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | 12 |
| Tresiba Flextouch U-200 | Insulin Degludec | 28 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 27 | suppressed |
| Olanzapine | Olanzapine | 27 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 26 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 26 | suppressed |
| Progesterone | Progesterone, Micronized | 26 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 25 | suppressed |
| Ondansetron Odt | Ondansetron | 25 | 19 |
| Dexlansoprazole Dr | Dexlansoprazole | 24 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 24 | suppressed |
| Vraylar | Cariprazine Hcl | 24 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 23 | suppressed |
| Lansoprazole | Lansoprazole | 23 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 23 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 22 | suppressed |
| Hydrocortisone | Hydrocortisone | 22 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 22 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Anastrozole | Anastrozole | 20 | suppressed |
| Lactulose | Lactulose | 20 | 11 |
| Linzess | Linaclotide | 20 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 19 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 18 | suppressed |
| Dexamethasone | Dexamethasone | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Entresto | Sacubitril/Valsartan | 18 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 18 | suppressed |
| Metronidazole | Metronidazole | 18 | 13 |
| Xtampza Er | Oxycodone Myristate | 18 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | 15 |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Primidone | Primidone | 17 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 16 | suppressed |
| Creon | Lipase/Protease/Amylase | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 12 |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Cefdinir | Cefdinir | 15 | 14 |
| Clonidine | Clonidine | 15 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 15 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 15 | suppressed |
| Cefadroxil | Cefadroxil | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 14 | suppressed |
| Nystop | Nystatin | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 13 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 13 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Phenobarbital | Phenobarbital | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Abilify Maintena | Aripiprazole | 12 | suppressed |
| Euthyrox | Levothyroxine Sodium | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Kelnor 1-50 | Ethynodiol D-Ethinyl Estradiol | 12 | suppressed |
| Kerendia | Finerenone | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 12 | suppressed |
| Probenecid | Probenecid | 12 | suppressed |
| Tacrolimus | Tacrolimus | 12 | suppressed |
| Zafirlukast | Zafirlukast | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Ciclopirox | Ciclopirox | 11 | suppressed |
| Epinephrine | Epinephrine | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $113.76 · 7 records | Novo Nordisk Inc | EVENITY, Korlym, Ozempic, QULIPTA, Rybelsus, TRELEGY ELLIPTA, UBRELVY, Wegovy | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error